The Single Entity Battle Continues: American Needle and the Seventh Circuit’s Hybrid Approach
This article is part of a Chronicle. See more from this Chronicle
Gabe Feldman, May 27, 2009
Courts have long struggled to articulate a coherent or sensible approach to applying the Sherman Act to sports leagues. While Major League Baseball avoided the complications through its infamous judicial exemption from the antitrust laws, antitrust decisions involving other professional sports leagues are riddled with inconsistencies and confusion. The Seventh Circuit recently added to the morass with its decision in American Needle. In American Needle, the plaintiff, a manufacturer and designer of sports apparel, brought an antitrust suit challenging the decision of the National Football League (“NFL”) and its teams (via NFL Properties) to enter into an exclusive licensing relationship with Reebok for the manufacture and sale of headwear bearing NFL team logos. The NFL moved for summary judgment, arguing that it was immune from Section 1 scrutiny because it functions as a single entity… [and]…sports leagues have long viewed the single entity defense as the antitrust “holy grail.”
Links to Full Content
Featured News
Spanish Minister Defends Record as Flood Crisis Casts Shadow on EU Role
Nov 22, 2024 by
CPI
UK Antitrust Regulator Signals Flexibility in Merger Reviews to Boost Economic Growth
Nov 21, 2024 by
CPI
US Supreme Court Declines to Hear Appeal in Google Antitrust Records Dispute
Nov 21, 2024 by
CPI
Matt Gaetz Withdraws from Consideration for US Attorney General Amid Controversy
Nov 21, 2024 by
CPI
Morocco Fines US Pharma Firm Viatris Over Merger Notification Breach
Nov 21, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Remedies Revisited
Oct 30, 2024 by
CPI
Fixing the Fix: Updating Policy on Merger Remedies
Oct 30, 2024 by
CPI
Methodology Matters: The 2017 FTC Remedies Study
Oct 30, 2024 by
CPI
U.S. v. AT&T: Five Lessons for Vertical Merger Enforcement
Oct 30, 2024 by
CPI
The Search for Antitrust Remedies in Tech Leads Beyond Antitrust
Oct 30, 2024 by
CPI